NO20082684L - F-, G-, H-, I- og K-krystallformer av imatinibmesylat - Google Patents

F-, G-, H-, I- og K-krystallformer av imatinibmesylat

Info

Publication number
NO20082684L
NO20082684L NO20082684A NO20082684A NO20082684L NO 20082684 L NO20082684 L NO 20082684L NO 20082684 A NO20082684 A NO 20082684A NO 20082684 A NO20082684 A NO 20082684A NO 20082684 L NO20082684 L NO 20082684L
Authority
NO
Norway
Prior art keywords
crystal form
crystal forms
imatinib mesylate
warm
preparation
Prior art date
Application number
NO20082684A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20082684L publication Critical patent/NO20082684L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20082684A 2005-11-25 2008-06-16 F-, G-, H-, I- og K-krystallformer av imatinibmesylat NO20082684L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
US74001805P 2005-11-28 2005-11-28
US74001605P 2005-11-28 2005-11-28
US74001705P 2005-11-28 2005-11-28
PCT/EP2006/011240 WO2007059963A1 (fr) 2005-11-25 2006-11-23 Formes cristallines f, g, h, i et k du mésylate d’imatinib

Publications (1)

Publication Number Publication Date
NO20082684L true NO20082684L (no) 2008-08-15

Family

ID=37847165

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082684A NO20082684L (no) 2005-11-25 2008-06-16 F-, G-, H-, I- og K-krystallformer av imatinibmesylat

Country Status (13)

Country Link
US (6) US7893076B2 (fr)
EP (3) EP2546248A1 (fr)
JP (2) JP5844508B2 (fr)
KR (4) KR20080078804A (fr)
CN (1) CN102351842B (fr)
AU (2) AU2006316823A1 (fr)
BR (1) BRPI0618993A2 (fr)
CA (3) CA2824307C (fr)
EC (1) ECSP088473A (fr)
MY (1) MY146403A (fr)
NO (1) NO20082684L (fr)
UY (1) UY29964A1 (fr)
WO (1) WO2007059963A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047530A1 (es) 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
KR20080078804A (ko) * 2005-11-25 2008-08-28 노파르티스 아게 이마티니브 메실레이트의 f, g, h, i 및 k 결정형
WO2009042803A1 (fr) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
JP2013519665A (ja) 2010-02-15 2013-05-30 リライアンス ライフ サイエンシズ ピーヴィーティー リミティッド メシル酸イマチニブのα形の製造方法
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (fr) 2010-12-29 2012-07-05 Cadila Healthcare Limited Nouveaux sels d'imatinib
EP2604596A1 (fr) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphes d'imatinib
WO2013189910A1 (fr) 2012-06-22 2013-12-27 Basf Se Cristaux multicomposants comprenant du mésilate d'imatinib et des agents de co-cristallisation choisis
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
US10478290B2 (en) * 2013-11-26 2019-11-19 Children's Medical Center Corporation Expandable stent valve
US10777331B2 (en) 2016-11-11 2020-09-15 Curium Us Llc Processes for generating germanium-68 with reduced volatiles
JP7263784B2 (ja) 2019-01-11 2023-04-25 日本精工株式会社 自在継手用ヨーク

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
TR200504337T1 (tr) * 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
AR047530A1 (es) 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
PT1720853E (pt) * 2004-02-11 2016-03-04 Natco Pharma Ltd Nova forma polimórfica de mesilato de imatinib e processo para a sua preparação
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
CN102085202A (zh) 2004-06-04 2011-06-08 比奥尼斯生命科学公司 伊马替尼在治疗肝脏疾病和病毒感染中的用途
WO2006024863A1 (fr) * 2004-09-02 2006-03-09 Cipla Limited Forme cristalline stable d'imatinib mesylate et son procede de preparation
WO2006048890A1 (fr) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Forme cristalline d'imatinib mesylate et procede d'elaboration
WO2006054314A1 (fr) * 2004-11-17 2006-05-26 Natco Pharma Limited Formes polymorphes de mesylate d'imatinibe
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
JP2009506014A (ja) * 2005-08-26 2009-02-12 ノバルティス アクチエンゲゼルシャフト イマチニブメシレートのデルタおよびイプシロン結晶形
KR20080078804A (ko) * 2005-11-25 2008-08-28 노파르티스 아게 이마티니브 메실레이트의 f, g, h, i 및 k 결정형

Also Published As

Publication number Publication date
CN102351842A (zh) 2012-02-15
CA2628330C (fr) 2015-06-16
KR20080078804A (ko) 2008-08-28
KR20130140909A (ko) 2013-12-24
EP2578580A1 (fr) 2013-04-10
US8198289B2 (en) 2012-06-12
US20120015955A1 (en) 2012-01-19
KR20130137721A (ko) 2013-12-17
US20130224288A1 (en) 2013-08-29
CA2824301C (fr) 2016-01-12
ECSP088473A (es) 2008-06-30
CA2824307A1 (fr) 2007-05-31
EP2546248A1 (fr) 2013-01-16
US20080268040A1 (en) 2008-10-30
US8592440B2 (en) 2013-11-26
US20120226038A1 (en) 2012-09-06
CN102351842B (zh) 2014-07-23
JP2014074067A (ja) 2014-04-24
CA2824307C (fr) 2016-03-29
CA2628330A1 (fr) 2007-05-31
EP1960380A1 (fr) 2008-08-27
BRPI0618993A2 (pt) 2011-09-20
US8846706B2 (en) 2014-09-30
US20110171301A1 (en) 2011-07-14
AU2011201286A1 (en) 2011-04-07
CA2824301A1 (fr) 2007-05-31
WO2007059963A1 (fr) 2007-05-31
US7893076B2 (en) 2011-02-22
US8633213B2 (en) 2014-01-21
MY146403A (en) 2012-08-15
AU2006316823A1 (en) 2007-05-31
JP5844508B2 (ja) 2016-01-20
JP2009517353A (ja) 2009-04-30
US8507515B2 (en) 2013-08-13
KR20130141712A (ko) 2013-12-26
UY29964A1 (es) 2007-06-29
US20120015027A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20064584L (no) Tetrahydropyridoindolderivater
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20066055L (no) Pyridinderivater
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
NO20081211L (no) Xantinderivater som selektive HM74A agonister
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20050828L (no) lndol-3-svovelderivater
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
NO20076635L (no) Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20064015L (no) Kondenserte derivater av pyrazol
NO20075992L (no) Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20074959L (no) Substituerte pyridinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application